Dr. Donald Heald has over 37+ years of clinical pharmacology (CP) and translational science experience in the pharmaceutical and biotech industries. Dr. Heald joined Biosion as a translational and clinical pharmacologist consultant and will help determine starting and efficacious dose predictions for FIH studies in early drug development.  Prior to starting his own consulting company, Dr. Heald worked at Janssen Biotherapeutics (JnJ) as Head of Discovery Translational Sciences and his group was responsible for determining the FIH starting dose and predicting an efficacious dose for biologics across multiple therapeutic areas.  Prior to Janssen Biotherapeutics, Don served as Vice President and Global Head of Clinical Pharmacology at Johnson and Johnson R&D and his group was responsible for conducting CP Phase 1-4 studies for all drug candidates in all therapeutic areas and global regulatory submissions. Don also led the Clinical Drug Disposition group at Rhone Poulenc Rorer, was a Sr. Scientist at The Upjohn Company and served as a Clinical Pharmacologist in the Cardio/Renal Division at the FDA.

Dr. Heald has a MS (pharmacology) and Ph.D. (pharmaceutical sciences (PK/PD)) degrees from West Virginia University.